Accuray's CyberKnife and TomoTherapy Systems Highlighted at World Conference on Lung Cancer
SUNNYVALE, Calif., July 7, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced new clinical data highlighting the ability of its CyberKnife® Robotic Radiosurgery System and its TomoTherapy® Radiation Therapy System to treat a wide range of patients with lung cancer and lung metastases. The new outcome data was presented at the 14th World Conference on Lung Cancer, the leading global forum for lung cancer and thoracic oncology research and practice, which took place July 3-7, 2011 in Amsterdam, The Netherlands.
The CyberKnife System, with its unique tracking and robotic correcting capabilities, is a dedicated radiosurgery system able to deliver destructive doses of radiation to tumors throughout the lung with the highest levels of accuracy, even for tumors close to critical structures such as the heart and esophagus. The TomoTherapy system has the ability to deliver both high quality intensity modulated radiation therapy for larger, complex tumors and ablative doses of radiation for smaller peripheral lung tumors that are away from critical structures, making it the premier hybrid radiation therapy system.
"The data presented this week at the World Conference on Lung Cancer demonstrate that CyberKnife and TomoTherapy deliver best-in-class radiation treatment options for a wide range of lung cancer patients," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "The unsurpassed flexibility of these systems, combined with a growing body of clinical evidence demonstrating low toxicity and long-term tumor control, make Accuray's technologies increasingly critical tools in treatment of even the